ArticleScientific reports2026
4-Phenylbutyrate mitigates renal pathology linked to ER stress related pathways in C57BL/6J mice with hindlimb unloading.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
4-Phenylbutyrate (4-PBA), a chemical chaperone known to reduce endoplasmic reticulum (ER) stress—a key contributor to kidney injury and fibrosis—has shown therapeutic potential in various disease models. However, the impact of hindlimb unloading (HU) on renal ER stress and its transcriptomic landscape remains poorly characterized. To our knowledge, this study provides the first comprehensive transcriptomic profiling of HU-induced renal alterations and their modulation by 4-PBA in C57BL/6J mice. To evaluate the protective effects of 4-PBA against HU-induced renal injury, mice were divided into three groups: ground-based controls (GC), HU mice receiving vehicle treatment (HU), and HU mice treated with 4-PBA. Renal histological and molecular alterations were assessed, and RNA sequencing was performed using the Illumina platform to characterize ER stress-related gene expression changes. HU induced significant ER stress-associated protein dysregulation and renal pathological alterations, which were partially attenuated by 4-PBA treatment. Gene Ontology enrichment analysis confirmed elevated ER stress signaling in HU kidneys and its reduction following 4-PBA administration. KEGG and Reactome pathway analyses further demonstrated modulation of multiple ER stress-associated and cytoprotective pathways with 4-PBA treatment. These findings provide transcriptomic-level evidence that 4-PBA mitigates HU-induced renal stress responses and support its potential as a therapeutic strategy for renal dysfunction associated with microgravity, prolonged immobilization, or sedentary conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.